Category: Pharma Trends
-

J&J Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront, Adding OLN324
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront. The deal would add OLN324, a Phase 3 candidate for wet AMD and diabetic macular edema. Early results against Vabysmo highlight differences in retinal imaging and leave open whether OLN324 can preserve vision with fewer injections.
-

FDA Approves Gazyva as First Treatment for Primary Membranous Nephropathy
The FDA approved Gazyva (obinutuzumab) to induce remission of proteinuria in adults with primary membranous nephropathy at risk of disease progression. In the Phase 3 MAJESTY trial, 36% of patients assigned to Gazyva achieved complete remission of proteinuria at week 104, compared with 6% assigned to tacrolimus, according to the FDA.
-

Bayer’s Sunharbo Wins FDA Approval for Secondary Stroke Prevention
Bayer’s Sunharbo (asundexian) is the first FDA-approved Factor XIa inhibitor. Its approval adds an oral treatment option alongside antiplatelet therapy for certain adults after a non-cardioembolic ischemic stroke or high-risk TIA. This article examines the clinical evidence, bleeding considerations and significance of the new drug class.
-

J&J’s Rybrevant Faspro Gains FDA Accelerated Approval for Head and Neck Cancer
Rybrevant Faspro expands beyond lung cancer with FDA accelerated approval for certain adults with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Here’s who qualifies and what the OrigAMI-4 study showed.
-

Inovio’s Voceryq Wins FDA Accelerated Approval for Recurrent Respiratory Papillomatosis
Inovio’s Voceryq wins FDA accelerated approval for adult RRP. A closer look at its DNA technology, clinical evidence and potential to ease repeated surgery.
-

Genmab’s Petosemtamab–Keytruda Combination Improves Survival in Phase 3 Head and Neck Cancer Trial
Genmab’s petosemtamab plus Keytruda improved survival in Phase 3 head and neck cancer testing. A closer look at the findings and their meaning for patients.
-

Astellas Secures Option on Audax’s IL-12 Cancer Therapy DAX-044
Astellas secured an option to license Audax’s DAX-044, a preclinical IL-12 immunotherapy designed to focus immune activation within the tumor microenvironment.
-

GSK and Hansoh’s B7-H3 ADC Improves Progression-Free Survival in Phase 3 Osteosarcoma Trial
GSK and Hansoh’s B7-H3 ADC Ris-Rez improved progression-free survival in a Phase 3 osteosarcoma trial, while substantial toxicity remains a concern.
-

Roche’s Divarasib Improves Survival in Phase 3 KRAS G12C Lung Cancer Trial
Roche’s divarasib improved median overall survival to 17.7 months versus 12.0 months with sotorasib or adagrasib in Phase 3 Krascendo 1. The findings inform treatment choice in KRAS G12C-mutated lung cancer but do not establish efficacy after KRAS-inhibitor resistance.
